HOOKIPA Pharma Inc. Overview
Pro stress-test →HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics based on its proprietary arenavirus platform. The company's pipeline targets cancer and infectious diseases, with programs in development for HPV+ head and neck cancers, hepatitis B, and HIV in collaboration with Gilead Sciences. The company is undergoing significant restructuring, including asset sales and voluntary delisting from NASDAQ.
Strategic Profile
Pro stress-test →HOOKIPA leverages a differentiated arenavirus platform that reprograms the immune system to target multiple therapeutic areas. The company has established strategic partnerships with Gilead Sciences for HB-400 (hepatitis B) and HB-500 (HIV) programs. However, recent asset dispositions signal a pivot toward liquidation, with immuno-oncology assets sold to NeoTrail Therapeutics in January 2026 and intention to delist from NASDAQ.
Competitive Landscape
Pro stress-test →HOOKIPA competes within the immuno-oncology and therapeutic vaccine space against companies like Immunomic Therapeutics, Celldex Therapeutics, and Altimmune. However, the competitive positioning is increasingly moot as the company executes its delisting and liquidation strategy. Prior to restructuring, the company differentiated through its arenavirus platform technology.
Industry Context
HOOKIPA Pharma Inc. operates in Biopharmaceutical / Immunotherapeutics.
Key facts
Founded: 2011 · Headquarters: New York, United States